RU2006113701A - Лечение респираторных заболеваний антителами против рецептора il-2 - Google Patents

Лечение респираторных заболеваний антителами против рецептора il-2 Download PDF

Info

Publication number
RU2006113701A
RU2006113701A RU2006113701/15A RU2006113701A RU2006113701A RU 2006113701 A RU2006113701 A RU 2006113701A RU 2006113701/15 A RU2006113701/15 A RU 2006113701/15A RU 2006113701 A RU2006113701 A RU 2006113701A RU 2006113701 A RU2006113701 A RU 2006113701A
Authority
RU
Russia
Prior art keywords
antibody
named
daclizumab
use according
amino acid
Prior art date
Application number
RU2006113701/15A
Other languages
English (en)
Russian (ru)
Inventor
Ричард С. ШЕЙМС (US)
Ричард С. ШЕЙМС
Original Assignee
Пдл Байофарма, Инк. (Us)
Пдл Байофарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пдл Байофарма, Инк. (Us), Пдл Байофарма, Инк. filed Critical Пдл Байофарма, Инк. (Us)
Publication of RU2006113701A publication Critical patent/RU2006113701A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
RU2006113701/15A 2003-09-23 2004-09-21 Лечение респираторных заболеваний антителами против рецептора il-2 RU2006113701A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50588303P 2003-09-23 2003-09-23
US60/505,883 2003-09-23
US55297404P 2004-03-12 2004-03-12
US60/552,974 2004-03-12

Publications (1)

Publication Number Publication Date
RU2006113701A true RU2006113701A (ru) 2007-11-10

Family

ID=34396276

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006113701/15A RU2006113701A (ru) 2003-09-23 2004-09-21 Лечение респираторных заболеваний антителами против рецептора il-2

Country Status (8)

Country Link
US (1) US20050089517A1 (enExample)
EP (1) EP1675615A1 (enExample)
JP (1) JP2007506681A (enExample)
AU (1) AU2004275860A1 (enExample)
BR (1) BRPI0414688A (enExample)
CA (1) CA2538737A1 (enExample)
RU (1) RU2006113701A (enExample)
WO (1) WO2005030252A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3087991A1 (en) 2003-11-08 2016-11-02 Prothera Biologics Composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
TR201808152T4 (tr) 2008-05-28 2018-07-23 Prothera Biologics Inc Kandan inter-alfa inhibitör proteinlerinin hazırlanması ve bunların bileşimi.
AU2009325088B2 (en) * 2008-12-10 2014-06-19 Duke University Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease
US9291626B2 (en) 2011-05-12 2016-03-22 Temple University—Of the Commonwealth System of Higher Education Diagnosis and treatment of chronic obstructive pulmonary disease (COPD)
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20190269765A1 (en) 2016-09-13 2019-09-05 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
BR112019011799B1 (pt) * 2016-12-13 2021-12-21 Delinia, Inc Proteína de fusão, proteína dimérica e composição farmacêutica
AU2018258466B2 (en) 2017-04-25 2025-05-22 Prothera Biologics, Inc. Methods for quantifying inter-alpha inhibitor proteins
EP3902584A4 (en) * 2018-12-29 2022-09-07 Kaleo, Inc. DEVICES AND METHODS FOR DELIVERING SUBSTANCES IN A PRE-FILLED SYRINGE
KR20220079576A (ko) * 2019-10-04 2022-06-13 알.피.쉐러 테크놀러지즈 엘엘씨 항-cd25 항체-메이탄신 접합체 및 이의 사용 방법
US12268847B1 (en) 2021-02-10 2025-04-08 Kaleo, Inc. Devices and methods for delivery of substances within a medicament container
GB202106254D0 (en) * 2021-04-30 2021-06-16 Teva Uk Ltd Inhaler system
CN118370816A (zh) * 2024-03-22 2024-07-23 中日友好医院(中日友好临床医学研究所) Il-2/抗il-2抗体免疫复合物的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473493A (en) * 1981-04-29 1984-09-25 Immunex Corporation Hybridoma antibody which inhibits interleukin 2 activity
US4411993A (en) * 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4845198A (en) * 1984-05-21 1989-07-04 Immunex Corporation Hybridoma antibody which binds IL-2 receptor
US5336489A (en) * 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
BR9604978A (pt) * 1995-04-14 1998-06-09 Glaxo Wellcome Inc Inalador com dose medida
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
DK1100829T3 (da) * 1998-07-27 2007-12-27 Novartis Ag Anvendelse af basiliximab til behandling af rheumatoid arthritis eller hudsygdomme
WO2002081508A2 (en) * 2001-04-06 2002-10-17 University Of Bristol Use of cd25 binding molecules in steroid-resistant patients
EP1578397B1 (en) * 2002-11-15 2012-12-26 Genmab A/S Human monoclonal antibodies against cd25

Also Published As

Publication number Publication date
JP2007506681A (ja) 2007-03-22
EP1675615A1 (en) 2006-07-05
WO2005030252A1 (en) 2005-04-07
AU2004275860A1 (en) 2005-04-07
BRPI0414688A (pt) 2006-11-28
CA2538737A1 (en) 2005-04-07
US20050089517A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
Raffray et al. Updates for the treatment of EGPA
CN109963577B (zh) 用于通过施用il-4r抑制剂治疗严重特应性皮炎的方法
JP2020128375A (ja) ベンラリツマブを使用して喘息の増悪率を低減する方法
JP2010043089A5 (enExample)
JP2010500360A5 (enExample)
JP2004536072A5 (enExample)
CN112153982A (zh) 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
IL303337B1 (en) Methods for treating chronic sinusitis with nasal polyps by adding an IL-4–R4 antagonist
JP2017507139A5 (enExample)
CN104755495A (zh) 通过施用il-4r拮抗剂治疗或预防哮喘的方法
JP2023520676A (ja) Ｉｌ－４ｒアンタゴニストを投与することによりアトピー性皮膚炎を処置するための方法
US20250034272A1 (en) Compositions and methods for treating severe asthma
JP2007506681A5 (enExample)
KR20250007566A (ko) Fcrn 길항제를 사용한 수포성 유천포창을 치료하는 방법
US20200231666A1 (en) Treatment paradigm
JP2016527326A (ja) ベンラリツマブによる喘息症状の改善方法
US20050089517A1 (en) Treatment of respiratory diseases with anti-IL-2 receptor antibodies
CA3239667A1 (en) Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, hypereosinophilic syndrome chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp
TWI870471B (zh) 全身性硬化症治療用醫藥組合物
JP2021501213A5 (enExample)
JP2014012683A5 (enExample)
KR20250094658A (ko) 항체, 조성물 및 치료 방법
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
IL285483B (en) Methods for the treatment of chronic sinusitis with nasal polyps by adding an il-4r antagonist
WO2026024319A1 (en) Treatment of obesity and obstructive sleep apnea

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20090127